These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31843376)

  • 1. Coverage of pharmacogenetic tests by private health insurance companies.
    Park SK; Thigpen J; Lee IJ
    J Am Pharm Assoc (2003); 2020; 60(2):352-356.e3. PubMed ID: 31843376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigating Insurance Policies in the United States for Gender-affirming Surgery.
    Cohen WA; Sangalang AM; Dalena MM; Ayyala HS; Keith JD
    Plast Reconstr Surg Glob Open; 2019 Dec; 7(12):e2564. PubMed ID: 32537307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Variation of Insurance Coverage for Gender-Affirming Facial Feminization Surgery.
    Gadkaree SK; DeVore EK; Richburg K; Lee LN; Derakhshan A; McCarty JC; Seth R; Shaye DA
    Facial Plast Surg Aesthet Med; 2021; 23(4):270-277. PubMed ID: 32865436
    [No Abstract]   [Full Text] [Related]  

  • 4. Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.
    Hikino K; Fukunaga K; Mushiroda T
    Drug Metab Pharmacokinet; 2018 Dec; 33(6):243-249. PubMed ID: 30360950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial insurance coverage for outpatient cardiac rehabilitation in patients with heart failure in the United States.
    Thirapatarapong W; Thomas RJ; Pack Q; Sharma S; Squires RW
    J Cardiopulm Rehabil Prev; 2014; 34(6):386-9. PubMed ID: 24866356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insurance Coverage of Facial Gender Affirmation Surgery: A Review of Medicaid and Commercial Insurance.
    Gorbea E; Gidumal S; Kozato A; Pang JH; Safer JD; Rosenberg J
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):791-797. PubMed ID: 33722109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in Insurance Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD.
    Yadav A; Vasquez P; Dolgin NH; Falchuk KR; Feuerstein JD
    J Clin Gastroenterol; 2019 Jul; 53(6):e239-e242. PubMed ID: 30439759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insurance Coverage Criteria for Bariatric Surgery: A Survey of Policies.
    Gebran SG; Knighton B; Ngaage LM; Rose JA; Grant MP; Liang F; Nam AJ; Kavic SM; Kligman MD; Rasko YM
    Obes Surg; 2020 Feb; 30(2):707-713. PubMed ID: 31749107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A National Review of Insurance Coverage of Noncancerous Breast Reconstruction.
    Klein M; Ha M; Yang A; Ngaage LM; Slezak S; Rasko Y
    Ann Plast Surg; 2021 Sep; 87(3):232-237. PubMed ID: 34397512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro fertilization: a cross-sectional analysis of 58 US insurance companies.
    Ha M; Drees A; Myers M; Finkelstein ER; Dandulakis M; Reindorf M; Roque DM; Beall SA; Slezak S; Rasko YM
    J Assist Reprod Genet; 2023 Mar; 40(3):581-587. PubMed ID: 36542313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Management of Diastasis Recti: A Systematic Review of Insurance Coverage in the United States.
    Rosen CM; Ngaage LM; Rada EM; Slezak S; Kavic S; Rasko Y
    Ann Plast Surg; 2019 Oct; 83(4):475-480. PubMed ID: 31524746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insurance companies' perspectives on the orphan drug pipeline.
    Handfield R; Feldstein J
    Am Health Drug Benefits; 2013 Nov; 6(9):589-98. PubMed ID: 24991385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Sectional Analysis of Insurance Coverage for Lymphedema Treatments in the United States.
    Lynn JV; Hespe GE; Akhter MF; David CM; Kung TA; Myers PL
    JAMA Surg; 2023 Sep; 158(9):920-926. PubMed ID: 37285151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Management of Gynecomastia: A Review of the Current Insurance Coverage Criteria.
    Rasko YM; Rosen C; Ngaage LM; AlFadil S; Elegbede A; Ihenatu C; Nam AJ; Slezak S
    Plast Reconstr Surg; 2019 May; 143(5):1361-1368. PubMed ID: 31033818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Regional Analysis of U.S. Insurance Reimbursement Guidelines for Massage Therapy.
    Miccio RS; Cowen VS
    Int J Ther Massage Bodywork; 2018 Mar; 11(1):11-16. PubMed ID: 29593843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Surgical Management of Migraines and Chronic Headaches: A Cross-sectional Review of American Insurance Coverage.
    Zhu K; Ha M; Finkelstein ER; Chaudry S; Hricz N; Ngaage LM; Rasko Y
    Ann Plast Surg; 2023 Jun; 90(6):592-597. PubMed ID: 37311314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers.
    Graf MD; Needham DF; Teed N; Brown T
    Per Med; 2013 May; 10(3):235-243. PubMed ID: 29768740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Insurance Coverage of Gender-Affirming Top Surgery in the United States.
    Ngaage LM; Knighton BJ; McGlone KL; Benzel CA; Rada EM; Bluebond-Langner R; Rasko YM
    Plast Reconstr Surg; 2019 Oct; 144(4):824-833. PubMed ID: 31568285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating the Insurance Landscape for Coverage of Reduction Mammaplasty.
    Rawes CMA; Ngaage LM; Borrelli MR; Puthumana J; Slezak S; Rasko YM
    Plast Reconstr Surg; 2020 Nov; 146(5):539e-547e. PubMed ID: 33141528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.